Psychopharmacological Agents During Pregnancy and Nursing
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43922633" target="_blank" >RIV/00216208:11120/21:43922633 - isvavai.cz</a>
Výsledek na webu
<a href="https://doi.org/10.1007/978-3-319-56015-1_268-1" target="_blank" >https://doi.org/10.1007/978-3-319-56015-1_268-1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/978-3-319-56015-1_268-1" target="_blank" >10.1007/978-3-319-56015-1_268-1</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Psychopharmacological Agents During Pregnancy and Nursing
Popis výsledku v původním jazyce
Decision-making about pharmacotherapy of mental disorders during pregnancy and lactation is a source of uncertainty in clinical practice. Potentially deleterious effects of drugs on the fetus and the infant are much feared; but at the same time, negative impact of untreated mental disorder have to be taken into account. Discontinuation of long-term medication increases greatly the risk of a relapse, may worsen the course of illness, and results in poor overall outcome. Drug pharmacokinetics is markedly changed throughout the pregnancy and postpartum; thus, the dosage has to be adjusted appropriately. It should be emphasized that mental disorders alone have been associated with numerous pre-, peri-, and postnatal complications and adverse effects on the fetus and the infant. Therefore, not all negative outcomes can be attributed to the medication. All psychotropic drugs cross placental barrier and pass into the maternal milk. The risk associated with drug treatment in pregnancy depends primarily on the period of exposure, gestational age. Teratogenic potential is greatest during the first trimester, neurobehavioral effects during the exposure in the last trimester, and withdrawal and intoxication with administration prior to the delivery. The chapter reviews available data on the risks and safety of antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics, and other psychopharmacological agents in pregnancy and nursing.
Název v anglickém jazyce
Psychopharmacological Agents During Pregnancy and Nursing
Popis výsledku anglicky
Decision-making about pharmacotherapy of mental disorders during pregnancy and lactation is a source of uncertainty in clinical practice. Potentially deleterious effects of drugs on the fetus and the infant are much feared; but at the same time, negative impact of untreated mental disorder have to be taken into account. Discontinuation of long-term medication increases greatly the risk of a relapse, may worsen the course of illness, and results in poor overall outcome. Drug pharmacokinetics is markedly changed throughout the pregnancy and postpartum; thus, the dosage has to be adjusted appropriately. It should be emphasized that mental disorders alone have been associated with numerous pre-, peri-, and postnatal complications and adverse effects on the fetus and the infant. Therefore, not all negative outcomes can be attributed to the medication. All psychotropic drugs cross placental barrier and pass into the maternal milk. The risk associated with drug treatment in pregnancy depends primarily on the period of exposure, gestational age. Teratogenic potential is greatest during the first trimester, neurobehavioral effects during the exposure in the last trimester, and withdrawal and intoxication with administration prior to the delivery. The chapter reviews available data on the risks and safety of antipsychotics, antidepressants, mood stabilizers, anxiolytics, hypnotics, and other psychopharmacological agents in pregnancy and nursing.
Klasifikace
Druh
C - Kapitola v odborné knize
CEP obor
—
OECD FORD obor
30104 - Pharmacology and pharmacy
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2021
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název knihy nebo sborníku
NeuroPsychopharmacotherapy
ISBN
978-3-319-56015-1
Počet stran výsledku
27
Strana od-do
1-27
Počet stran knihy
754
Název nakladatele
Springer
Místo vydání
Cham
Kód UT WoS kapitoly
—